# Anti-Tac for Treatment of Leukemia

> **NCT00001941** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 34 (actual)

## Conditions studied

- HTLV-I Infection
- T Cell Leukemia

## Interventions

- **BIOLOGICAL:** daclizumab

## Key facts

- **NCT ID:** NCT00001941
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-12
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2012-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001941, "Anti-Tac for Treatment of Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00001941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*